Amgen Inc v. Celltrion USA Inc
CA3 Affirms Enbrel Patent Infringement, Reverses Willfulness Finding
ca3 · 2025-06-05 · Mixed · Impact: 60/100
Amgen Inc v. Celltrion USA Inc, decided by Third Circuit on June 5, 2025, resulted in a mixed outcome. The Third Circuit affirmed the District Court's finding of infringement of Amgen's patents for it...